secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001213900-25-032071
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 3.02, 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies closes $8M asset acquisition from Ayala; eliminates $20M milestones, cuts royalty to 1.5%
--------------------------------------------------------------------------------

- Total consideration $8M: $400k cash to Ayala, $100k to third party, $7.5M in stock (4,774,637 shares at VWAP).
- Eliminated $3.5M Biologics License filing milestone and $16.5M in sales milestones for OST-HER2.
- Royalty on OST-HER2, ADXS-503, ADXS-504 reduced from 10% to 1.5% of net sales (to Univ. of Pennsylvania).
- Added three clinical-stage candidates (OST-AXAL for HPV, OST-503 for NSCLC, OST-PSA for prostate) and 8 preclinical constructs.
- Issued 2,164,215 shares and a warrant for 2,166,381 shares (exercise $0.001, 3-yr term); additional 444,041 shares pending stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/0001213900-25-032071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/ea0238051-8k_ostherapies.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer